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1. INTRODUCTION membranes was much greater than to the par- 
Treatment of young and adult rats with estrone, 
estradiol (Ez) or ovine prolactin (oPRL) [1,2] 
significantly induces the appearance of specific 
PRL binding sites in liver and lung membranes. To 
characterize completely and purify such a receptor 
it needs to be solubilized from the membrane. 
There are few reports on the solubilization, 
purification and characterization of PRL receptors 
under conditions allowing the specific study of 
their binding properties [3-61. The commonly used 
detergent Triton X-100 has been shown to cause 
aggregation of 1251-oPRL during binding studies 
[3] and thus necessitated the use of 1251-hGH. 
Recently, the zwitterionic detergent 3-[(3-cholam- 
idopropyl) dimethylammonia]- 1 propane-sulfo- 
nate.2 Hz0 (CHAPS) has been used successfully 
to solubilize muscarinic cholinergic receptors from 
rat brain cortex [7] and was therefore used for this 
study of solubilization of the PRL receptor from 
Ez-induced male rat liver. 
ticulate preparation, suggesting an unmasking of 
cryptic sites. Gel filtration of the 12’1- 
oPRL-receptor complex on Sepharose 6B revealed 
an estimated M, - 340 000. These results show that 
CHAPS is particularly suitable for solubilization 
of PRL receptors since the properties of the recep- 
tor are maintained and since CHAPS does not in- 
terfere with the binding of “‘1-oPRL. 
2. MATERIALS AND METHODS 
Binding of ‘251-oPRL to PRL receptor solubiliz- 
ed with 0.5% CHAPS was dependent upon the 
protein concentration. This receptor demonstrated 
the hormonal specificity typical of the membrane- 
bound PRL receptor and was bound to an anti- 
PRL receptor. Binding to the CHAPS-solubilized 
oPRL (NIH-P-S15; 30.5 IU/mg), human GH 
(hGH; NIAMDD-hGH-RP-I), human PRL 
(hPRL; NIAMDD-hPRL-RP-1) rat PRL (rPRL- 
B-3) rat GH (rGH; GH-B-6) human FSH (hFSH; 
HS-1) were kindly supplied by the National 
Pituitary Agency of the NIAMDD. All the other 
reagents were purchased from commercial sources 
detailed in [ 14, 151. Anti-PRL-receptor anti-serum 
(no. 151), raised in sheep against a partially 
purified rabbit mammary gland PRL receptor, was 
kindly provided by Dr P.A. Kelly (Molecular En- 
docrinology Laboratory, CHUL, Quebec). 
Sprague-Dawley female and male rats (200 g body 
wt) were used. For the induction of PRL binding 
sites, the male rats received daily S.C. injections of 
Ez (0.4 mg) mixed with 10% PVP (w/v) for 7 days. 
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2.1. Preparation of membrane fractions 
The crude membrane fractions containing PRL- 
receptors were prepared from livers of Ez-treated 
male rats as in [8]. The resultant 100 000 x g pellet 
was resuspended in 5 vol. (per gram of original 
tissue weight) ice-cold buffer containing 0.01 M 
Tris-HCl, 0.002 M KCl, 0.01 M MgCl2 and 0.1% 
sodium azide (pH 7.6). The protein concentration 
as determined by a modification [9] of the method 
in [lo] was - 200 pg/O. 1 ml suspension. 
2.3. Binding assay 
“‘1-oPRL (1 rig/O.. 1 ml) was incubated with 0.1 
ml particulate or solubilized membranes in the 
absence or presence of excess unlabelled oPRL (1 
pg/O. 1 ml) to determine non-specific binding as in 
[ 131. Incubations were carried out in 0.3 ml final 
vol. at 20°C for 44 h. After incubation, the bound 
hormone was separated from the free by precipita- 
tion and filtration as in [ 141. Filters were placed in 
plastic tubes and radioactivity was measured in an 
automatic y-counter. 
2.2. Iodination of oPRL 
oPRL was iodinated by the lactoperoxidase 
method in [l] and purified by chromatography on 
Sephadex G-100 as in [12]. The specific activity 
was - 80 Ci/g. 
2.4. Solubilization 
Solubilization was performed by adding 0.5% 
(w/v) CHAPS in 0.01 M Tris-HCI (pH 7.6) to the 
100 000 x g resuspended membrane pellet, follow- 
Unlabelled Hormone (ngltube) 
Fig. 1. Hormone specificity of “‘I-oPRL binding to CHAPS-solubilized liver membrane: 1251-oPRL (1 rig/O.. 1 ml) was 
incubated with solubilized receptors (as in section 2) with increasing concentrations of unlabelled competing hormones. 
The specific binding of “‘1-oPRL was expressed as a percentage of that obtained in the absence of unlabelled hormone. 
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ed by homogenization and incubation for 60 min 
at 0°C. The reagent mixture was then centrifuged 
at 100000 x g for 90 min at 4°C and the resultant 
supernatant used as the solubilized receptor 
preparation in binding studies. 
2.5. Gel filtration 
The hormone-receptor complex was 
chromatographed on a Sepharose 6B column (58 
x 2.5 cm) at 5°C and eluted with 0.1 M Tris-HCl 
buffer (pH 7.6) containing 0.01% CHAPS. The 
column was calibrated with several marker pro- 
teins. The void volume (V,) was determined by us- 
ing blue dextran 2000 and the total volume (K with 
Na”‘l. The chromatographic characteristic was 
estimated by calculation of the elution constant 
(Kav) based on the elution volume (V, and the 
formula: 
3. RESULTS 
In preliminary studies, the ability of a variety of 
detergents to solubilize PRL receptors from the 
female rat liver was evaluated and only CHAPS 
(0.5%) was found to be both efficient in solubiliz- 
ing the receptor and did not interfere in the binding 
assay. The use of 20.75% CHAPS resulted in in- 
activation of -50% of the binding activity of the 
solubilized receptor. 
In view of the high concentration of PRL recep- 
tors in livers of Ez-treated male rats [l, 151, these 
receptors were solubilized with 0.5% CHAPS for 
the purpose of characterization. CHAPS- 
solubilized membranes demonstrated 75% greater 
binding activity than observed with the 100000 x 
g pellet. Under these conditions 74% of the total 
microsomal membrane proteins were solubilized. 
‘251-oPRL specific binding increased as a function 
of CHAPS-solubilized membrane protein concen- 
tration, reaching 55% of total cpm with 350 lg 
protein/tube. Non-specific binding was not 
significantly affected. In hormone specificity 
studies only unlabelled hormones with lactogenic 
properties effectively competed for the binding of 
i2’I-oPRL (fig. 1). 
Scatchard analysis [16] of the competition data 
with oPRL revealed two populations of binding 
Bound (fmollmg protein 1 
Fig. 2. Scatchard analysis of binding of ‘*‘I-pPRL to 
CHAPS solubilized liver membranes from Ez-treated 
male rats: The competition data of fig. 1 were analyzed 
by Scatchard analysis [16]. The ordinate represents he 
ratio of bound/free and the abscissa the ‘amount 
(fmol/mg) of 1251-oPRL bound to CHAPS-solubilized 
receptors. The negative slope of the plot yields the 
affinity constant (K.) and the intercept on the abscissa 
yields the binding capacity. The results presented are 
from a representative experiment which was repeated 3
times. 
sites for the solubilized membranes, with K, values 
of 2.4 x 10” and 1.3 x lo9 l/m01 and respective 
binding capacities of 141.5 and 619.5 fmol/mg 
protein (fig. 2). 
The addition of increasing concentrations of a 
sheep anti-PRL receptor antiserum to either par- 
ticulate or CHAPS-solubilized membranes 
resulted in similar, concentration-related inhibi- 
tion of “‘1-oPRL binding. The addition of control 
serum only did not significantly affect the binding, 
in the concentration range used (fig. 3). 
Fig. 4 shows the elution pattern from Sepharose 
6B of CHAPS-solubilized liver membrane from 
E2-treated rats, incubated with “‘1-oPRL in the 
absence or presence of excesss unlabelled oPRL. 
The radioactive peak of fraction 32 (Kav = 0.15) 
represents the hormone-receptor complex since 
excess unlabelled oPRL resulted in its 
disappearance. 
4. DISCUSSION 
In this study the hepatic receptors for PRL from 
E2-treated rats were solubilized with 0.5% CHAPS 
and partially characterized using ‘251-oPRL as a 
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Fig. 3. Effect of anti-PRL receptor antiserum on the binding of ‘*‘I-oPRL particulate or CHAPS-solubilized liver 
membranes, from Ez-treated rats: 1251-oPRL (1 ng/O.l ml) was incubated for 44 h at 20°C with particulate membranes 
(300pg protein/reaction) or with CHAPS-solubilized membranes (8Opg protein/reaction), in the presence of increasing 
concentrations of either control serum or an antiserum from sheep, raised against a partially purified rabbit mammary 
PRL receptor. Binding was expressed as a percentage of binding in the absence of serum. 
tracer in the binding studies. In contrast to Triton 
X-100, CHAPS did not alter the prolactin 
molecule as determined by its elution pattern on 
Sepharose 6B and did not interfere with its binding 
activity. Previously lz51-hGH was used as a tracer 
in characterization of the Triton-solubilized recep- 
tors, since it has been shown not to be affected by 
the detergent, while 12SI-oPRL was shown to ag- 
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Fig. 4. Sepharose 6B chromatography of CHAPS- 
solubilized “$1-oPRL-receptor complex. CHAPS- 
solubilized liver membranes of Ez-treated male rats were 
incubated with ‘251-oPRL in the absence (0) or presence 
(0) of excess unlabelled oPRL as in section 2. The in- 
cubation mixture was appiied to Sepharose 6B column 
(58 x 2.5 cm) and eluted with 0.01% CHAPS in 0.01 M 
Tris-HCl buffer (pH 7.6). Fractions (3.8 ml) were col- 
lected, and the radioactivity was measured in an 
automatic y-counter. The column was equilibrated for 
M, determination using the following markers, whose 
position was monitored at 280 nm: (1) urease (480000); 
(2) BGG (160000); (3) BSA (69~); (4) myoglobin 
(17000). 
gregate in Triton X-100 [3,17]. Even though hGH 
and oPRL bind to the same molecular lactogenic 
sites in the target tissue membr~es and subse- 
quently elicit similar biological responses, hGH 
has been shown to differ considerably from oPRL 
in a number of important points. While oPRL has 
a high affinity only for lactogenic sites, hGH is 
thought to recognize strongly at least 2 types of 
sites, namely lactogenic and somatogenic 1: 181 and 
it has even been suggested that these two sites will 
not explain fully its binding properties to liver 
membranes [19]. oPRL and hGH have different 
primary structures [20] resulting in different three- 
dimensional geometry of the hormones. Thus it 
seems likely that the environmental requirements 
for each hormone’s binding to its membrane recep- 
tors are different. Indeed, membrane modification 
differentially affects the binding of hGH and 
oPRL [21]. Thus it was important to find a 
detergent which did not interfere with 1251-oPRL 
binding to characterize solubilized PRL receptors. 
Out of a variety of detergents tudied, CHAPS 
was able to solubilize as much as 74% of the par- 
ticulate membrane protein and did not interfere in 
the binding activity of ‘2SI-oPRL. Further, 1251- 
oPR1 binding to this same solubilized preparation 
was 75% greater than to the original particulate 
membranes prepared from livers of Ez-treated 
male rats. This suggests the possibility that 
solubilization might have exposed masked or cryp- 
tic binding sites and is in keeping with findings that 
estradiol is capable of inducing cryptic PRL sites in 
livers of neonatally-treated female mice [22] and 
with the demonstration of cryptic cell-surface 
receptors in cultured rat mammary tumour cells 
[23]. This hypothesis is supported by the 
demonstration, by Scatchard analysis 1161 of two 
types of PRL binding sites in the solubilized 
hepatic membranes. 
The hormonal specificity of the solubilized PRL 
receptor was apparently not affected by the 
solubilization process, since all of the lactogenic 
hormones effectively competed for ‘251-oPRL 
binding, as shown for the membrane-bound recep- 
tors [8]. The lack of effect of CHAPS solubiliza- 
tion on the binding characteristics of the recogni- 
tion site of the PRL receptor is further 
demonstrated by the inhibition of ‘251-oPRL by a 
specific PRL receptor antibody. The antiserum 
was equally effective on membrane-bound and on 
solubilized PRL receptors. This same antiserum 
has been shown to inhibit effectively the 
physiolo~cal action of PRL in both liver and 
mammary gland in vitro, in parallel to inhibition 
of PRL binding [24,25]. 
In gel chromatography studies on Sepharose 6B, 
the ‘251-oPRL-receptor complex was estimated to 
have an A4, - 340 000. Earlier studies of Triton 
X-lo-solubilized rat liver or rabbit rn~rn~y 
gland membranes using hGH as their tracer ob- 
tained M-values for the lactogenic receptor from 
>150000-330000 [3-6,171. In those studies, the 
particulate membrane solubilization was done at 
room temperature (20-2YC) for 30-60 min. 
While this study was in preparation two studies of 
solubilization of PRL receptors with zwitterionic 
detergents were reported [26,27]. Using zwittergent 
3-12 PRL receptors were solubilized from rabbit 
mammary gland at 4°C for 1 h [26]. In that study, 
the n/l, obtained was identical to the value 
presented here. In 1271 the PRL receptor was 
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solubilized from lactating mouse liver membranes, 
also using CHAPS, but at room temperature 
(23°C) for 30 min with constant stirring and found 
the Mr to be 57000-61000 for the complex; they 
suggested that the peptide thus obtained might 
represent a binding subunit of the PRL receptor. It 
is possible that at 0°C (on ice), a milder solubiliza- 
tion is obtained such that a larger PRL receptor en- 
tity, rather than only a binding subunit, is 
separated from the membrane fraction. Never- 
theless, one cannot rule out the possibility that we 
are looking at an aggregate of a smaller subunit 
not to mention the species and tissue differences. 
In support of the present findings, the M, of a solu- 
ble PRL receptor studied in the 100000 x g super- 
natant cytosolic fraction of liver from either 
female or Ez-treated male rats was identical to that 
of the CHAPS (O”(Z)-solubilized PRL receptor 
(submitted). Since no detergent was used for the 
study of the soluble cytosolic PRL receptor, it is 
implied that the use of CHAPS does not interfere 
with the M, determination, and that we are in fact 
dealing with the PRL receptor molecule. 
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